VK2735 Maintenance Study Could Be A Big Test For Viking Therapeutics Stock

• Viking Therapeutics has begun an exploratory oral maintenance dosing study of VK2735 in adults with obesity, complementing ongoing large Phase 3 VANQUISH trials in both non diabetic and type 2 diabetic populations.
• The move to test multiple oral and injectable maintenance regimens highlights management’s focus on long term obesity treatment patterns and the operational demands of chronic weight management therapies.
• We will now look at how Viking Therapeutics’ investment narrative could be influenced by this VK2735 maintenance dosing expansion.

Scan how Viking Therapeutics fits into the broader obesity and metabolic treatment story by comparing it with 34 healthcare AI stocks that could also reshape weight management and related care.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you need to believe VK2735 can move from clean clinical data into a real obesity franchise, across both injectable and oral formats. The new oral maintenance study fits that story. It tests whether VK2735 can support long term weight control with different dosing patterns, which matters for chronic use and eventual commercial design.

For the near term, the main swing factor still sits with the large Phase 3 VANQUISH trials and the planned oral Phase 3 program, not this relatively small maintenance add on. The biggest risk stays the same. Viking remains a loss making, clinical stage biotech that depends on cash reserves and successful late stage outcomes.

Among recent updates, the projected earnings per share of a loss of about $1 and the expectation of continued unprofitability keep attention squarely on Viking Therapeutics’ cash burn and execution. Rising research and development spend to $345 million in 2025 and an annual loss of $358.5 million underline how dependent the business is on external funding.

That context frames the new VK2735 maintenance work. A broader dosing data set could support future commercialization plans if VANQUISH-1 and VANQUISH-2 read out well, but it also implies continued operating costs and the possibility of future equity or debt raises. Analyst optimism exists, yet the real operational catalyst still lies in whether late stage trials progress cleanly and on time.

Viking Therapeutics’ narrative projects US$118.5 million in revenue and US$12.9 million in earnings by 2029. This implies yearly top line growth from effectively zero revenue and an earnings improvement of about US$372.5 million from a loss of US$359.6 million today.

Uncover why Viking Therapeutics' fair value indicates a 225% potential upside to its current price that could narrow quickly.

Exploring Other Perspectives

Some of the most optimistic analysts frame the oral VK2735 program itself as the catalyst. Before this news, the bullish narrative already assumed Viking Therapeutics could reach US$497.5 million in revenue and US$62.2 million in earnings by 2029. That is far above consensus, and the fresh maintenance data may eventually push those views to shift again.

Explore 3 other Viking Therapeutics fair value estimates, including one that suggests as much as 232% upside from the current price.

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• See our latest analysis for Viking Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Looking For More Investment Ideas Beyond Viking Therapeutics?

Once you have formed a view on Viking Therapeutics, it can help to compare that thesis with other opportunities that fit different risk and quality profiles by using the Simply Wall St Screener.

• If you want potential upside with strict balance sheet discipline, scan our list of solid balance sheet and fundamentals (25 results) to see which businesses pair financial resilience with fundamental strength.
• For those looking for value oriented ideas, sort through 28 high quality undervalued stocks to find companies where quality metrics and current pricing appear out of sync.
• If you prefer early stage potential with smaller market caps, review the 14 elite penny stocks with strong financials that meet tighter financial filters instead of relying on hype alone.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com